Clinical Study 2 – BERT Study
The Dutch National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM) in cooperation with the Spaarne Gasthuis, a hospital in the Dutch city of Hoofddorp, is recruiting patients for the BERT study (Booster pertussis vaccine study).
Further information on the Clinical Study can be found directly on the Website of the Rijksinstituut voor Volksgezondheid en Milieu, RIVM. Visit: http://www.rivm.nl/Onderwerpen/V/Vaccinonderzoek/Kinkhoest/BERT_studie (all information is shown in Dutch)
Where does the study take place?
Spaarnepoort 1, 2134 TM Hoofddorp, The Netherlands
Why is the BERT study conducted?
The BERT study investigates how cells in the blood respond to a recurrent vaccination against whooping cough. It determines whether this response depends on age, the number of vaccines that someone has received during his/her childhood and the type of vaccine that has been administered to someone in his/her youth. The study investigates the immune response in the blood of people of different ages. In the blood the amount of antibodies that someone produces for whooping cough is measured. Further, the reaction of the memory cells in the blood is investigated in different ways. These results can contribute to better vaccines in the future, thus optimizing the protection against whooping cough.
Whooping cough is an infection of the respiratory tract. This infection is caused by the bacterium Bordetella pertussis (B. pertussis) and is characterized mainly by a typical cough that often lasts for 3-4 months. The disease is also known as 'hundred-day cough'. Whooping cough is transmitted through droplet infection. In coughing patients, infectiousness lasts three weeks after the onset of the symptoms. Also someone without symptoms can infect others.